Importantly, we offer a direct head-to-head comparison between two widely used antidiabetic drug classes—SGLT-2 inhibitors (empagliflozin) and DPP-4 inhibitors (sitagliptin)—within a real-world type 2 diabetes population. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.